Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct;12(10):e70023.
doi: 10.1002/iid3.70023.

Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort

Lucie Lafarge  1 , Charles Pilette  1   2 , Céline Bugli  3 , Antoine Froidure  1   2
Affiliations
Observational Study

Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort

Lucie Lafarge et al. Immun Inflamm Dis. 2024 Oct.

Abstract

In this observational study, we show that switching biologics in severe asthma results in a high proportion of controlled patients.

PubMed Disclaimer

Conflict of interest statement

Charles Pilette discloses unrestricted research grants from GlaxoSmithKline, Chiesi, Sanofi and AstraZeneca, outside of the submitted work. Antoine Froidure discloses unrestricted research grants from Boehringer Ingelheim, outside of the submitted work. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sequence of biologics in 127 patients with severe asthma; showing the switch sequence and clinical response for all the patients over time.
See this image and copyright information in PMC

References

    1. Eger K, Kroes JA, Ten Brinke A, Bel EH. Long‐term therapy response to anti‐IL‐5 biologics in severe asthma‐A real‐life evaluation. J Aller Clin Immunol. 2021;9(3):1194‐1200. - PubMed
    1. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343‐373. - PubMed
    1. Matsumoto‐Sasaki M, Simizu K, Suzuki M, et al. Clinical characteristics of patients and factors associated with switching biologics in asthma. J Asthma Aller. 2022;15:187‐195. - PMC - PubMed
    1. Menzies‐Gow AN, McBrien C, Unni B, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Aller. 2022;15:63‐78. - PMC - PubMed
    1. Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single‐center retrospective study. J Asthma Aller. 2021;14:609‐618. - PMC - PubMed

Publication types